Alphaplant Pharmaceutical (“Alphaplant”) is funded privately and was established in 2020, our passion for growing cannabis has been fueled by the Founder’s vision and Investors drive for producing the best-quality of GMP-certified medical cannabis. Alphaplant will finalise the transfer of land and GMP license by the end of Q3 – 2022. Then Alphaplant will enter the construction phase with the goal of completing the first infrastructure expansion of circa 6500 sqm by Q2 – 2023. From which Alphaplant will endeavor to produce its first harvest of GMP-certified cannabis by end of Q3 – 2023.The future plans are to extend the infrastructure facility to circa 17800 sqm in full production. Alphaplant aims to be a trust brand for distributing the best-qualify of GMP-certified medical cannabis to the local and international markets.

We aim to be a trusted brand for providing best quality GMP-certified medicinal cannabis product which will be distributed to the local and advancing international markets. South Africa is positioned to be a global leader in the growing and producing of medical cannabis, more than 40 countries worldwide have approved the doctor prescribe use of medicinal cannabis. Globally the medicinal cannabis market was valued at US$20.4billion in 2017 and is expected to grow up to US$90.1billion in 2026. Alphaplant Pharmaceutical will invest into infrastructure located in Southern Africa which will position itself to produce the best quality GMP-certified medicinal cannabis products and grow to be a trusted brand locally and internationally.